The effect of recombinant zoster vaccine on patients with chronic obstructive pulmonary diseases: A multi‐institutional propensity score‐matched cohort study

Author:

Tsai Ya‐Wen12ORCID,Zhang Bin3,Wu Jheng‐Yan4ORCID,Hsu Wan‐Hsuan5,Liu Ting‐Hui6,Chuang Min‐Hsiang5,Huang Po‐Yu5ORCID,Lai Chih‐Cheng78ORCID

Affiliation:

1. Division of Preventive Medicine Chi Mei Medical Center Tainan Taiwan

2. Department of Medical Laboratory Sciences and Biotechnology Fooyin University Kaohsiung Taiwan

3. Division of Biostatistics and Epidemiology Cincinnati Children's Medical Center Cincinnati Ohio USA

4. Department of Nutrition Chi Mei Medical Center Tainan Taiwan

5. Department of Internal Medicine Chi Mei Medical Center Tainan Taiwan

6. Department of Psychiatry Chi Mei Medical Center Tainan Taiwan

7. Department of Intensive Care Medicine Chi Mei Medical Center Tainan Taiwan

8. School of Medicine, College of Medicine National Sun Yat‐sen University Kaohsiung Taiwan

Abstract

AbstractAlthough the recombinant zoster vaccine (RZV) has demonstrated efficacy in reducing the risk of herpes zoster (HZ) for individuals aged 50 years and older, its effectiveness in patients with chronic obstructive pulmonary disease (COPD) remains uncertain. This study was conducted to assess the effect of RZV on the risk of HZ in COPD patients. A multi‐institutional propensity score‐matched retrospective cohort study was conducted using the TriNetX Research network, including individuals aged 40 years or older with COPD from January 1, 2018, to December 31, 2022. Patients with a history of HZ or prior zoster vaccination were excluded. The primary outcome was HZ occurrence, with secondary outcomes including severe and nonsevere HZ. After propensity score matching, each 17 431 patients receiving RZV and unvaccinated patients were included. The vaccinated group had a significantly lower risk of HZ compared to the unvaccinated group (HR, 0.62; [95% confidence intervals] 95% CI, 0.51–0.75, p < 0.01). Similar risk reductions were observed for nonsevere HZ (HR, 0.61; 95% CI, 049–0.75, p < 0.01) and severe HZ (HR, 0.53; 95% CI, 0.38–0.73, p < 0.01). Further subgroup analyses demonstrated consistent risk reductions across age (50–59, 60–69, 70–79, and ≥80 years), sex, and comorbidities, except for individual aged 40–49 years. This study confirms the effectiveness of RZV in reducing HZ risk in patients with COPD aged 50 years and older, supporting its administration in this population. However, vaccination rates remain low, highlighting the need for improved vaccination strategies in this high‐risk group. Efforts to enhance vaccine uptake are warranted to reduce HZ morbidity.

Publisher

Wiley

Reference39 articles.

1. Herpes zoster: a review of clinical manifestations and management;Patil A;Viruses,2022

2. A 70‐year‐old woman with shingles: review of herpes zoster;Whitley RJ;JAMA,2009

3. Systematic review of incidence and complications of herpes zoster: towards a global perspective;Kawai K;BMJ Open,2014

4. Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review;Pan CX;Ther Adv Vaccines Immunother,2022

5. Meta‐regression of herpes zoster incidence worldwide;Curran D;Infect Dis Ther,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3